Episode 146

Direct Meds: How to Build an AI-First Company With In-House AI Agents

Adam Pivko
Adam Pivko
Chief Marketing Officer

In this episode we talked about:

  • Why AI demos can succeed while the same systems fail in production
  • What evaluation, governance, observability, and security practices enterprise AI needs to scale
  • Why narrowly scoped domain agents often perform better than agents designed to do everything
  • How existing processes and “golden datasets” make strong foundations for enterprise AI use cases
  • Why lower-risk, repeatable tasks are often the best place to begin AI adoption
  • How to evaluate whether AI automation actually delivers enough ROI to justify its cost
  • Why retailers increasingly need to think about discoverability inside AI agents, not just traditional search

🎧 Listen now on Apple Podcasts, Spotify, or YouTube

Episode highlights:

02:26 – What it means to become an AI-first business

‍07:12 – Building an in-house AI tech stack

‍10:16 – Using AI to connect marketing data end to end

‍13:25 – The challenge of using AI with sensitive health data

‍18:48 – Why the right AI leader can transform adoption

Adam's bottom line: Being AI-first doesn't have to mean fewer people. At Direct Meds, it means building a proprietary stack of agents that makes a 440-person team faster, connecting every ad dollar through to LTV, and working within HIPAA's limits on patient data. The shift didn't take off until the company hired an AI maestro whose job is to train AI to understand each leader's role, not to learn that role himself.

FAQ

Adam Pivko is the CMO of Direct Meds, a fast-growing telehealth company he joined when his own brand was acquired into it. His first real job out of university was door-to-door sales selling photocopiers, which convinced him nobody prints anymore and that he wanted to sell online instead. From there he worked his way through affiliate networks, payment companies, anti-fraud, CRMs and business automation tools, and large ecommerce conglomerates before launching his own brand.
It isn't about replacing people. Adam acknowledges headlines about telehealth competitors potentially becoming billion-dollar companies with almost no employees, but says that isn't how Direct Meds operates. The company is hands-on with patients and providers and has grown to around 440 people. For Direct Meds, AI is a layer of efficiency that makes everyone on the team more effective, first, and a way to improve patients' lives, second. It isn't primarily an OpEx-cutting exercise.
Carefully, and mostly in places that don't interpret, store, or connect data to an individual. Adam's examples include responding to off-hours comments with safeguarded answers drawn from approved lists, helping people navigate the patient portal, and keeping patients informed about what to expect next in their medication journey. He says the medications themselves are widely available, so what makes Direct Meds different is making progress feel inevitable, and AI helps with that. Protecting personal health information (PHI) is still the biggest open problem on the roadmap. When the team tests outside AI tools, it scrubs PHI from the data first so those tools never see it, but that pushes the analysis into aggregates and loses the niche situations that could move the needle.
Flux is Direct Meds' proprietary in-house AI tech stack, which Adam describes as an army of internal agents. The team started investing in it roughly 8 to 10 months before the episode. It uses OpenRouter heavily to tap into multiple LLMs, on the belief that there's a best model for each business case, whether that's static images, video, content, or research. Flux connects to the company's task management software and is growing into a central, trusted source for data access, reporting, cross-departmental research, and project management. An AI maestro oversees the agents to keep them performing, and new ones are added as other departments bring their needs forward. Adam calls himself a power user.
Direct Meds has a build-it rather than buy-it culture and is very proprietary about its technology. When a problem comes up, the team looks at what AI solutions exist and then usually builds its own. Adam is clear that cost savings aren't the reason. Building in-house gives them more flexibility, more control, and tools that sit deeper inside their own ecosystem. He also agrees with the SaaStr idea, raised by Kailin, that the CMO should be using the most AI tokens in the company, and says he's probably using more than Direct Meds' CTO.
Adam's media buying philosophy is to get 1% better every day through constant testing and optimization rather than swinging for the fences. A core part of that is learning from every dollar spent, because winning and losing ads are both buying you data. The most impactful thing AI has done for his team is connect the full stream, from ad creative and platform metrics through the funnel journey to LTV, so they can see where the gaps are across patient acquisition and patient experience. AI has also compressed timelines and cut down on cross-departmental slowdowns, but Adam still leans on his team's creativity and expertise, which he believes produces a higher win rate than chasing speed alone.
The AI maestro is the person who made Direct Meds' AI-first shift work. His expertise is rolling out AI, and he has just enough business understanding to take an end result a leader wants and work through the steps to get there. As Adam puts it, his job isn't to fully understand the CMO's role; it's to train AI to understand it. That spares executives from scoping every AI project themselves, and it helped bring in team leaders who weren't using AI at all. Direct Meds hired for the role rather than pivoting someone into it. Adam's view is that if you're investing in a proprietary in-house AI stack, you need someone who spends a lot of time following how the models are evolving, so you should find the right person rather than repurpose one.
Start small and let the opportunities show themselves. Adam thinks of AI as an unlimited-energy, no-ego intern: the more data, access, and control you give it, the more it can do, but it should earn those responsibilities with early wins before it gets a promotion. He encourages teams to go after micro wins rather than waiting for a perfect long-term plan, because using the tools reveals what's possible, and once people try it, he says, they get addicted.

Want to be featured on The Ecommerce Toolbox?

We feature senior ecommerce leaders with real things to say. If you've led something worth talking about, we want to hear from you.

Apply to be a guest →

Other episodes

See all episodes

Audit your site today

Understand the revenue impact of all errors on your site and how to swiftly reproduce and resolve.